Policy Developments - The new draft of the "Further Optimization of Drug Procurement Policy" has circulated in the industry, emphasizing the procurement of medical consumables alongside drugs, enhancing policy flexibility [1] - Since the implementation of the "4+7" volume-based procurement in 2018, the government has organized 10 batches of drug procurement and 5 batches of high-value medical consumables procurement, successfully procuring a total of 435 types of drugs [1] Drug and Device Approvals - Johnson & Johnson's Guselkumab has received approval for a new indication in China for treating moderate to severe active ulcerative colitis in adults who have inadequate response to traditional therapies or biologics [2] - Fosun Pharma's subsidiary has received FDA approval to conduct clinical trials for LBP-ShC4, a live biotherapeutic product aimed at treating androgenetic alopecia, with a cumulative R&D investment of approximately 0.17 million yuan by April 2025 [3] - Reindeer Biologics announced that its CAR-T cell therapy product, Ikigai, has received orphan drug designation from the Saudi FDA for treating relapsed or refractory multiple myeloma in adults [4] Capital Markets - HAYA Therapeutics has completed a $65 million Series A financing round to accelerate the clinical development of its long non-coding RNA-targeted candidate drug HTX-001 for heart failure [5] Regulatory Actions - Pace Double Forest Biopharmaceuticals received administrative regulatory measures from the Shanxi Securities Regulatory Bureau due to internal control deficiencies and inaccurate information disclosure [6] - Maiwei Biotech's chairman received a notice of investigation from the China Securities Regulatory Commission for suspected short-term trading, which is not expected to significantly impact the company's daily operations [7] - Tibet Weixin Pharmaceutical's subsidiary has withdrawn its drug registration application for a pediatric compound amino acid injection, which is not yet marketed in China [8]

Company News - China First Heavy Industries' legal representative and chairman, Lu Wenjun, is under investigation for serious violations of discipline and law, and the company will soon hold a board meeting to appoint a director to act in the chairman's role [2] - Hengda plans to acquire high-precision CNC grinding business assets from German company SMS Maschinenbau GmbH for €8.5 million, funded by its own or raised funds, aiming to enhance R&D capabilities and product offerings in intelligent CNC equipment [3] - Longpan Technology's subsidiaries signed a strategic cooperation agreement to sell 150,000 tons of lithium iron phosphate cathode materials, with total sales expected to exceed ¥5 billion from 2025 to 2029 [4] - Hongta Securities' chairman proposed a share buyback plan using self-owned funds, with a total amount between ¥100 million and ¥200 million, and a buyback period of 12 months following shareholder approval [5] Performance Growth - Xiaoming's chicken product sales revenue increased by 73.86% year-on-year in April [7] - New Tian Green Energy's power generation rose by 16.91% year-on-year in April [7] - Changyuan Power completed 2.779 billion kWh of power generation in April, a year-on-year increase of 17.61% [7] - New Wufeng's pig sales volume reached 408,100 heads in April, up 36.31% year-on-year [7] - Shuguang's vehicle sales in April were 155 units, reflecting a year-on-year growth of 70.33% [7] - Shengnong's sales revenue in April was ¥1.533 billion, a slight increase of 0.68% year-on-year [7] Other Matters - Fushun Special Steel is absorbing its wholly-owned subsidiary Xinxing Plate [12] - Landai Technology plans to acquire an 18% stake in its subsidiary Chongqing Taiguan [12] - Wencan's subsidiary secured a new customer for a three-in-one motor shell project [12] - Yitong Century won a project bid worth ¥228 million from China Mobile [12] - Postal Savings Bank's application for a specific object A-share issuance was approved by the Shanghai Stock Exchange [12] - Traffic Bank's application for a specific object A-share issuance was also approved [12] - Sanhua Intelligent Control is issuing overseas listed shares (H-shares) with approval from the China Securities Regulatory Commission [12] - Potential Energy Trust plans to raise no more than ¥676 million through a private placement [12]